US FDA says all doses of Lilly's weight-loss and diabetes drug now available
)'s weight-loss drug Zepbound and diabetes drug Mounjaro are now available, the U.S. Food and Drug Administration's updated shortage list showed on Friday.Lilly's Mounjaro has been on the U.S. FDA's shortage list since late 2022, while Zepbound was added to the list in April this year.
The health regulator added that even when all doses of a drug are listed as available, additional criteria are considered before moving a drug off the shortages list.Lilly did not immediately respond to a Reuters request for comment.Surging demand for Mounjaro and Zepbound has led Lilly to invest billions of dollars in boosting their production of these drugs.
Currently, all doses of diabetes drug Ozempic are available in the United States, while three doses of Wegovy remain in limited supply.Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly's Zepbound and Mounjaro now available in U.S. after shortages, FDA saysDemand for weight loss and diabetes drugs has trounced supply for months, pushing Eli Lilly and its rival Novo Nordisk to invest billions to ramp up…
Read more »
Eli Lilly's Zepbound and Mounjaro now available in U.S. after shortages, FDA saysDemand for weight loss and diabetes drugs has trounced supply for months, pushing Eli Lilly and its rival Novo Nordisk to invest billions to ramp up…
Read more »
Woman arrested after deadly shooting in Cleveland’s Clark Fulton neighborhoodThe Cuyahoga County Medical Examiner identified the victim as Dontez Lilly.
Read more »
Lilly's tirzepatide cuts heart failure risks, company saysMustafa Fattah is a medical fellow with the NBC News Health and Medical Unit.
Read more »
Eli Lilly's weight loss drug Zepbound cuts heart failure risks in late-stage studyThe data adds to mounting evidence that Zepbound and other popular GLP-1 drugs have health benefits beyond promoting weight loss and regulating blood sugar.
Read more »
Weight Loss Drug Zepbound Could Lower Heart Failure Risks, Eli Lilly SaysTy Roush is a New York City-based breaking news reporter who frequently covers Russia’s invasion of Ukraine, the automotive industry and sports money. He joined Forbes in 2022 and has covered Exxon acquiring Pioneer for nearly $60 billion, a mysterious respiratory illness affecting dogs across the U.S.
Read more »